Cortistatin
- Category
- Brain & Cognition
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A neuropeptide related to somatostatin, explored for sleep, anti-inflammatory, and pain effects. The case rests almost entirely on animal and mechanism studies; human evidence is minimal to absent, so benefits remain speculative. It shares somatostatin's growth-hormone suppression, may cause GI effects, and has essentially no human safety data. Not an approved drug in the US, and supply is unregulated research-grade product of uncertain purity.
Read Full recordStudied uses & evidence
Studied uses(5)
Enhancement of slow-wave sleep via non-somatostatin receptor mechanisms
LowDeep sleep effects confirmed in rats; underlying receptor differs from somatostatin, not fully identified.
Potent anti-inflammatory effects — suppresses TNF-alpha, IL-6, IL-12 in multiple disease models
LowReduces inflammatory markers across multiple animal disease models; no human studies exist.
Inhibition of vascular smooth muscle cell proliferation and neointimal hyperplasia
LowShown in human cells and mouse models; a single study, no human dosing trials.
Evidence limits
- Evidence Level
- Preclinical
Cortistatin research is predominantly preclinical, with strong evidence for anti-inflammatory, sleep-promoting, cardiovascular protective, and neuroprotective effects in animal models. At least four small human studies have been conducted (Broglio et al. 2002-2004, Giordano et al. 2006), demonstrating cortistatin's endocrine effects via IV infusion in healthy volunteers and patients with acromegaly or prolactinoma. No large-scale Phase II/III therapeutic trials have been completed. The peptide's unique receptor profile (binding both somatostatin receptors and the ghrelin receptor) suggests therapeutic potential distinct from somatostatin analogs like octreotide.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Diabetes or hypoglycemia risk
ModerateLike somatostatin, cortistatin inhibits insulin and glucagon secretion. Can disrupt glucose homeostasis.
Growth hormone deficiency
ModerateCortistatin suppresses GH secretion similarly to somatostatin. May worsen GH deficiency.
General cautions
Pregnancy
AbsoluteNo human safety data. Pleiotropic effects on multiple receptor systems make risk unpredictable.
Risk summary(3)
Risks = level of concern: High · Moderate · Low · Theoretical
Suppression of growth hormone secretion (shared with somatostatin)
ModeratePotential gastrointestinal effects from somatostatin receptor activation
ModerateMinimal human safety data available
High
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.